Mar 28th, 2020
Digital therapeutics (DTx) are clinically validated digital solutions with proven positive effects on disease management and outcomes. in this episode, Jessica Shull, European Lead for the Digital Therapeutics Alliance, shaping advocacy and organizational engagement for the DTx industry in European countries, explains what DTx are, why are they relevant clinical interventions, how do clinical trials for medications differ from clinical trials for digital therapeutics. Jessica also explains what digital therapeutics are and how they should be differentiated from digital diagnostics and more.
As written by the Digital Health Alliance, DTx have immense potential in the coronavirus pandemic, because patient access to and utilization of digital therapeutics could improve health outcomes, consequently reducing chronic disease-related hospitalizations, mitigating additional pressures on healthcare providers during the COVID-19 outbreak. Their use could reduce vulnerable populations’ potential coronavirus exposure.
Announcement: Jessica Shull will be at the Eyeforpharma virtual conference taking place between March 30th and April 3rd! Go to: https://www.eyeforpharma.com/barcelona/